

Patient Name:
Date of Service:

Colon cancer (G9084-G9089)

Circle **one** code from each area. Available, potentially relevant guidelines are listed below, by code.
Circle source of guideline consulted (ASCO and/or NCCN), or circle if no guideline available/patient on clinical trial (bottom of page).

Primary Focus of Visit	
G9050	Work-up, evaluation, or staging at the time of cancer diagnosis or recurrence
G9051	Treatment decision-making after disease is staged or restaged, Discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy
G9052	Surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future
G9053	Expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future
G9054	Supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies
G9055	Other, unspecified service not otherwise listed
Disease State	
G9084	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N0, M0 with no evidence of disease progression, recurrence, or metastases
G9085	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, N0, M0 with no evidence of disease progression, recurrence, or metastases
G9086	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-4, N1-2, M0 with no evidence of disease progression, recurrence, or metastases
G9087	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease
G9088	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease
G9089	Colon cancer , limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, not yet determined, under evaluation, pre-surgical, or not listed
Practice Guideline Use	
G9056	Management adheres to guidelines
G9057	Management differs from guidelines as a result of patient enrollment in an institutional review board approved clinical trial
G9058	Management differs from guidelines because the treating physician disagrees with guideline recommendations
G9059	Management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment
G9060	Management differs from guidelines for reason(s) associated with patient comorbid illness or performance status not factored into guidelines
G9061	Patient's condition not addressed by available guidelines
G9062	Management differs from guidelines for other reason(s) not listed

Potentially Relevant Codes	Potentially Relevant Guidelines
G9084 / G9085 / G9086 / G9087 / G9088 / G9089	ASCO: 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer
G9084 / G9085	ASCO Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
G9084 / G9085 / G9086	Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline
G9084 / G9085 / G9086 / G9087 / G9088 / G9089	NCCN Clinical Practice Guidelines in Oncology: Colon Cancer
General	ASCO: 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors
	ASCO: 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of ASCO
	ASCO: Platelet Transfusion for Patients with Cancer
	ASCO: Recommendations for the Use of Antiemetics
	ASCO: Use of Epoetin in Patients with Cancer
	NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain
	NCCN Clinical Practice Guidelines in Oncology: Antiemesis
	NCCN Clinical Practice Guidelines in Oncology: Cancer- and Treatment-Related Anemia
	NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue
	NCCN Clinical Practice Guidelines in Oncology: Distress Management
	NCCN Clinical Practice Guidelines in Oncology: Fever and Neutropenia
	NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors
	NCCN Clinical Practice Guidelines in Oncology: Palliative Care
NCCN Clinical Practice Guidelines in Oncology: Pediatric Cancer Pain	
NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology	

Source of guideline consulted: **ASCO** **NCCN** **Both ASCO & NCCN** **No guideline available** **Clinical Trial**

For a complete listing of all 2006 Oncology Demonstration Project (ODP) resources, go to ASCO's 2006 ODP Page at <http://www.asco.org/2006demo>.

This document is a practice tool designed to facilitate physician participation in the CMS 2006 Oncology Demonstration Project and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines and this document do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this document are voluntary. The practice guidelines and additional information are available at <http://www.asco.org/guidelines>.